153 related articles for article (PubMed ID: 35715641)
1. Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma.
Shindoh J; Kawamura Y; Kobayashi M; Akuta N; Okubo S; Matsumura M; Suzuki Y; Hashimoto M
J Gastrointest Surg; 2022 Aug; 26(8):1637-1646. PubMed ID: 35715641
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma.
Shindoh J; Kawamura Y; Kobayashi Y; Kobayashi M; Akuta N; Okubo S; Suzuki Y; Hashimoto M
Ann Surg Oncol; 2021 Nov; 28(12):7663-7672. PubMed ID: 33904001
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
4. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
5. Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma.
Kawamura Y; Akuta N; Shindoh J; Matsumura M; Okubo S; Tominaga L; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kozuka T; Kumada H
Clin J Gastroenterol; 2023 Feb; 16(1):1-12. PubMed ID: 36344851
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Wang L; Lin L; Zhou W
Pharmacol Ther; 2024 May; 257():108634. PubMed ID: 38499069
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
[TBL] [Abstract][Full Text] [Related]
8. Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment.
Lin PT; Teng W; Jeng WJ; Lin CC; Lin CY; Lin SM; Sheen IS
J Formos Med Assoc; 2024 Jul; 123(7):788-795. PubMed ID: 38310071
[TBL] [Abstract][Full Text] [Related]
9. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma.
Rapposelli IG; Shimose S; Kumada T; Okamura S; Hiraoka A; Di Costanzo GG; Marra F; Tamburini E; Forgione A; Foschi FG; Silletta M; Lonardi S; Masi G; Scartozzi M; Nakano M; Shibata H; Kawata K; Pellino A; Vivaldi C; Lai E; Takata A; Tajiri K; Toyoda H; Tortora R; Campani C; Viola MG; Piscaglia F; Conti F; Fulgenzi CAM; Frassineti GL; Rizzato MD; Salani F; Astara G; Torimura T; Atsukawa M; Tada T; Burgio V; Rimini M; Cascinu S; Casadei-Gardini A
ESMO Open; 2021 Aug; 6(4):100190. PubMed ID: 34144271
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
Rimini M; Kudo M; Tada T; Shigeo S; Kang W; Suda G; Jefremow A; Burgio V; Iavarone M; Tortora R; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Kumada T; Iwamoto H; Aoki T; Goh MJ; Sakamoto N; Siebler J; Hiraoka A; Niizeki T; Ueshima K; Sho T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
ESMO Open; 2021 Dec; 6(6):100330. PubMed ID: 34847382
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy.
Luo J; Huang Z; Wang M; Li T; Huang J
BMC Gastroenterol; 2022 Mar; 22(1):108. PubMed ID: 35260095
[TBL] [Abstract][Full Text] [Related]
13. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
Sun X; Zhang Q; Mei J; Yang Z; Chen M; Liang T
BMC Cancer; 2022 Mar; 22(1):293. PubMed ID: 35305593
[TBL] [Abstract][Full Text] [Related]
14. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
15. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
16. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Cai M; Huang W; Huang J; Shi W; Guo Y; Liang L; Zhou J; Lin L; Cao B; Chen Y; Zhou J; Zhu K
Front Immunol; 2022; 13():848387. PubMed ID: 35300325
[TBL] [Abstract][Full Text] [Related]
17. A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma.
Kobayashi S; Fukushima T; Ueno M; Moriya S; Chuma M; Numata K; Tsuruya K; Hirose S; Kagawa T; Hattori N; Watanabe T; Matsunaga K; Suzuki M; Uojima H; Hidaka H; Kusano C; Suzuki M; Morimoto M
BMC Cancer; 2022 May; 22(1):517. PubMed ID: 35525913
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.
Llovet JM; Vogel A; Madoff DC; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo M
Cardiovasc Intervent Radiol; 2022 Apr; 45(4):405-412. PubMed ID: 35119481
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
[TBL] [Abstract][Full Text] [Related]
20. The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.
Yamaoka K; Kodama K; Kawaoka T; Kosaka M; Johira Y; Shirane Y; Miura R; Yano S; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Uchikawa S; Uchida T; Fujino H; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Miki D; Imamura M; Takahashi S; Nagao A; Chayama K; Aikata H
PLoS One; 2022; 17(1):e0262675. PubMed ID: 35041693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]